SangStat cyclosporine
Executive Summary
Patent issued for SangStat's proprietary generic cyclosporine formulation, Sang-35, SangStat CFO James Hinrichs says. The patent covers both liquid and capsule dosage forms. SangStat is awaiting FDA approval of its generic version of Novartis' Neoral and has arranged manufacturing partnerships with Gensia Sicor for the bulk substance and Lilly for finished product. The branded generic will be marketed as part of a "CycloSystem," accompanied by SangStat's CycloTech dosing device, which increases compliance by sounding an alarm at dosing time, ejecting the controlled liquid dose for consumption, and storing dosing information in a "smart chip" for up to one year